17
Oct

After years of clinical and regulatory setbacks, Repros Therapeutics was finally on the path to submitting its testosterone treatment to the FDA, scheduling a prefiling meeting for November with hopes of handing the drug in by year’s end. But the agency has had some second thoughts, changing the agenda for the meeting and indefinitely delaying Repros’ plans.

…read more

Source: Repros plummets as the FDA deals a blow to its low-T hopes

    

0 No comments